Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Kurth

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Genes|December 23, 2022
Clonal Elimination of the Pathogenic Allele as Diagnostic Pitfall in <i>SAMD9L</i>-Associated NeuropathyK Eggermann, R Meyer, M Begemann, et al.
FEBS Letters|February 29, 2000
Different epitopes are required for gp130 activation by interleukin-6, oncostatin M and leukemia inhibitory factorA Timmermann, S Pflanz, J Grötzinger, et al.
Parkinsonism & Related Disorders|February 20, 2019
PDE10A mutation in two sisters with a hyperkinetic movement disorder - Response to levodopaC Knopp, M Häusler, B Müller, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopesI Kurth, U Horsten, S Pflanz, et al.
Molecular Syndromology|January 8, 2013
A Novel Homozygous WDR72 Mutation in Two Siblings with Amelogenesis Imperfecta and Mild Short StatureA Kuechler, J Hentschel, I Kurth, et al.
Bone|July 21, 2019
Biallelic CSGALNACT1-mutations cause a mild skeletal dysplasiaR Meyer, S Schacht, L Buschmann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 1999
Importance of the membrane-proximal extracellular domains for activation of the signal transducer glycoprotein 130I Kurth, U Horsten, S Pflanz, et al.
Clinical Genetics|December 16, 2016
Mutations in CRLF1 cause familial achalasiaA Busch, M Žarković, C Lowe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2021
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic <i>NRG1</i> FusionsIgor Odintsov, Allan J W Lui, Whitney J Sisso, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 9, 2022
Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG)D Martin, T Schreckenbach, P Ziegler, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Genes|December 23, 2022
Clonal Elimination of the Pathogenic Allele as Diagnostic Pitfall in <i>SAMD9L</i>-Associated NeuropathyK Eggermann, R Meyer, M Begemann, et al.
FEBS Letters|February 29, 2000
Different epitopes are required for gp130 activation by interleukin-6, oncostatin M and leukemia inhibitory factorA Timmermann, S Pflanz, J Grötzinger, et al.
Parkinsonism & Related Disorders|February 20, 2019
PDE10A mutation in two sisters with a hyperkinetic movement disorder - Response to levodopaC Knopp, M Häusler, B Müller, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopesI Kurth, U Horsten, S Pflanz, et al.
Molecular Syndromology|January 8, 2013
A Novel Homozygous WDR72 Mutation in Two Siblings with Amelogenesis Imperfecta and Mild Short StatureA Kuechler, J Hentschel, I Kurth, et al.
Bone|July 21, 2019
Biallelic CSGALNACT1-mutations cause a mild skeletal dysplasiaR Meyer, S Schacht, L Buschmann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 1999
Importance of the membrane-proximal extracellular domains for activation of the signal transducer glycoprotein 130I Kurth, U Horsten, S Pflanz, et al.
Clinical Genetics|December 16, 2016
Mutations in CRLF1 cause familial achalasiaA Busch, M Žarković, C Lowe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2021
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic <i>NRG1</i> FusionsIgor Odintsov, Allan J W Lui, Whitney J Sisso, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 9, 2022
Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG)D Martin, T Schreckenbach, P Ziegler, et al.
Pageof 3